How should daily spotting be managed in a patient using the etonogestrel implant (Nexplanon)?

Management of Daily Spotting with Nexplanon

Start mefenamic acid 500 mg three times daily for 5 days during bleeding episodes as first-line therapy, which achieves significant bleeding cessation within 7 days. 1

Initial Evaluation Before Treatment

Before attributing daily spotting to Nexplanon, systematically exclude:

• Pregnancy – this is the mandatory first step in any evaluation of bleeding changes 1
• Sexually transmitted infections – unscheduled bleeding can indicate STI presence 1
• New uterine pathology – specifically polyps, fibroids, or structural abnormalities that could explain the bleeding 1
• Drug interactions – review all concomitant medications that may affect bleeding patterns 1

Understanding the Context of Daily Spotting

Daily spotting is a common occurrence with Nexplanon, not a contraceptive failure:

• Approximately 34% of users experience infrequent spotting during the first year 1
• About 18% have prolonged bleeding and 7% experience frequent bleeding episodes 1
• The bleeding pattern in the first 3 months broadly predicts future patterns, though individual variation exists 2
• In 75% of reference periods, total bleeding-spotting days are fewer than or comparable to natural menstrual cycles, but occur at unpredictable intervals 3

First-Line Pharmacologic Management: NSAIDs

Mefenamic acid is the most effective NSAID option:

• Dose: 500 mg three times daily for 5 days during each bleeding episode 1
• This regimen achieves significant bleeding cessation within 7 days compared to placebo 1
• Celecoxib 200 mg once daily for 5 days is an alternative NSAID with demonstrated efficacy 1

Avoid ibuprofen as primary therapy – it shows inconsistent results across studies, with one trial showing benefit and another showing no difference versus placebo 1

Second-Line Hormonal Management (When NSAIDs Fail)

If mefenamic acid does not control bleeding adequately:

• Low-dose combined oral contraceptives for 10–20 days during bleeding episodes are highly effective, with 76.2% of women achieving bleeding cessation within 7 days (compared to 35.7% with NSAIDs alone) 1
• Estrogen-only therapy for 10–20 days can reduce bleeding days when COCs are unsuitable 1
• Prescribing these temporizing measures significantly improves implant continuation rates (67.1% vs 40% retention at one year) 4

Critical Safety Precautions

• Screen for cardiovascular contraindications before prescribing estrogen, particularly history of spontaneous coronary artery dissection 1
• Avoid tranexamic acid in patients with cardiovascular risk factors due to thrombotic event risk 1
• Do not use doxycycline alone – it does not improve bleeding cessation and offers no therapeutic benefit 1

When to Consider Alternative Contraception

If bleeding remains unacceptable despite medical management:

• The levonorgestrel-releasing intrauterine system (20 µg/day) is the most effective alternative, reducing menstrual blood loss by 71–95% 1
• More than half of adolescent implant users discontinue before 24 months, with abnormal bleeding being the most common reason 1
• Offer counseling about alternative long-acting reversible contraceptive methods for women with persistent, refractory bleeding 1

Common Pitfalls to Avoid

• Never assume all bleeding is benign – always exclude pregnancy, STIs, and structural pathology first 1
• Do not dismiss patient concerns – effective pre-insertion counseling about expected bleeding patterns reduces discontinuation rates, but ongoing bleeding still warrants active management 1
• Avoid aspirin – it shows no significant difference in bleeding episode length and offers no therapeutic advantage 1
• Remember that younger age and lower BMI are associated with higher rates of bothersome bleeding complaints 4